Transitioning To Advanced Therapies For DFUs: Are Four Weeks And 50 Percent The Magic Numbers?

Chanel Houston, DPM, Samirah Mohammed, DPM, and Peter A. Blume, DPM, FACFAS

1. Fife C. Is HBOT cost-effective for diabetic foot ulcers? Podiatry Today. 2009:22(6):18-24.
2. Stillman R, Steinberg J. Current concepts in treating diabetic foot wounds. Podiatry Today. 2003:16(3):12-18.
3. Landsman A. Emerging concepts in healing diabetic foot ulcers. Podiatry Today. 2011;24(3):42-28.
4. Mulder G, Armstrong D, Seaman S. Standard, appropriate, and advanced care and medical-legal considerations: part one — diabetic foot ulcerations. Wounds. 2003;15(4):92–106.
5. Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg. 1998; (176 2A Suppl):5S-10S.
6. Malay D, Margolis D, et al. The Incidence and risks of failure to heal after lower extremity amputation for the treatment of diabetic neuropathic foot ulcer. J Foot Ankle Surg. 2006;45(6):366–374.
7. Wound Ostomy and Continence Nurses Society (WOCN). Guideline for management of wounds in patients with lower-extremity arterial disease. Wound Ostomy and Continence Nurses Society, Glenview, IL. 2002.
8. Blume P, Walters J. et al. Comparison of negative pressure wound therapy using Vacuum-Assisted Closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care. 2008;31(4):631-636.
9. Martson WA, Hanft J, Norwood P, Pollak R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26(6):1701–1705.
10. Veves A, Falanga V, Armstrong DA, Sabolinski ML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24(2):290-295.
11. Robson MC, Payne WG, Garner WL, Biundo J, Giacalone VF, Cooper DM, Ouyang P. Integrating the results of phase IV (postmarketing) clinical trial with four previous trials reinforces the position that Regranex (becaplermin) gel 0.01% is an effective adjunct to the treatment of diabetic foot ulcers. J Appl Res. 2005;5:35–45.
12. Mannari RJ, Payne WG, Ochs DE, Walusimbi M, Blue M, Robson MC. Successful treatment of recalcitrant, diabetic heel ulcers with topical becaplermin (rh-PDGF-BB) gel. Wounds. 2002;14(3):116 –121.
13. Peters EJ, Lavery LA, Armstrong DG, Fleischli JG. Electric stimulation as an adjunct to heal diabetic foot ulcers: a randomized clinical trial. Arch Phys Med Rehabil. 2001;82(6):721–725.
14. Argenta LC, Morykwas MJ. Vacuum-assisted closure: a new method for wound control and treatment: clinical experience. Ann Plast Surg. 1997;38(6):563–576.
15. Sheehan P, Jones P. A percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete wound healing in a 120-week prospective trial. Diabetes Care. 2003;26(6):1879-1882.
16. Boulton A, Kirsner R, Vileikyte L. Neuropathic diabetic foot ulcers. N Engl J Med. 2004;351(1):48-55.
17. Snyder R, Cardinal M. A post-hoc analysis of reduction in diabetic foot ulcer size at 4 weeks as a predictor of healing by 12 weeks. Ostomy Wound Management. 2010;56(3):44-50.
18. Lavery L, Barnes S, et al. Prediction of healing for postoperative diabetic foot wounds based on early wound area progression. Diabetes Care. 2008;31 (1): 626-636.
19. American Diabetes Association. National Diabetes Fact Sheet 2011.
20. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: General Information and National Estimates on Diabetes in the United States, 2011. Atlanta, GA, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
21. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22(3):382-387.

Add new comment